rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LTRN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Rodman & Renshaw downgrades Lantern Pharma stock rating on CEO exit
      15h agoInvesting.comLTRN
      Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone

      DALLAS, November 10, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, and its wholly owned subsidiary Starlight Therapeutics today announced the publication of Phase 1a clinical data for LP-184 (zirdafulven) in patients with recurrent GBM. LP-184 is being developed as STAR-001 for central nervous system (CNS) cancers. The paper appears in the October 2026 issue of Cancer Research Communications, a peer-reviewed journal of the American Association f

      Nov 10Yahoo FinanceLTRN
      Lantern Pharma at ThinkEquity Conference: AI drug push gains pace
      Oct 15Investing.comLTRN
      Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 15

      Detailed price information for Lantern Pharma Inc (LTRN-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailLTRN
      Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026

      DALLAS, October 08, 2026--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026

      Oct 8Yahoo FinanceLTRN
      Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
      Oct 8Yahoo FinanceLTRN
      Lantern Pharma (NASDAQ: LTRN) Receives Taiwan Approvals to Advance Phase 2 HARMONIC(TM) Trial

      Detailed price information for Lantern Pharma Inc (LTRN-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailLTRN
      Lantern Pharma receives Taiwan approval for LP-300 trial expansion
      Oct 7Investing.comLTRN
      Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

      DALLAS, October 07, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC™ trial of LP-300. The Taiwan Food and Drug Administration (TFDA) approved the amended protocol earlier in September, and the lead Taiwan site received local Institutional Review Board (IRB) approval on September 29, 2026. The lead site is now open to

      Oct 7Yahoo FinanceLTRN
      Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering

      Investor Brand Network Press Release.

      Oct 1The Globe and MailLTRN
      Lantern Pharma closes $4 million stock offering
      Sep 30Investing.comLTRN
      Lantern Pharma raises $4M in registered direct offering
      Sep 29Investing.comLTRN
      Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

      DALLAS, September 29, 2026--Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern", the "Company" or "we"), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 3,669,725 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.09 per share (or pre-funded warrant in lieu thereof) i

      Sep 29Yahoo FinanceLTRN
      Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development - Slideshow (NASDAQ:LTRN) 2026-09-24
      Sep 24Seeking AlphaLTRN
      Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent

      Investor Brand Network Press Release.

      Sep 23The Globe and MailLTRN
      Lantern Pharma receives patent allowance for LP-284 cancer drug
      Sep 22Investing.comLTRN
      New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

      BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.

      Sep 19Yahoo FinanceACXPLTRN
      Lantern Pharma Q2 2026 Earnings Call: Complete Transcript
      Sep 18BenzingaLTRN
      Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap

      Detailed price information for Bayerische Motoren Werke ADR (BMWYY) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailLTRN
      Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

      DALLAS, September 17, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), the company’s wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeu

      Sep 17Yahoo FinanceLTRN
      New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)

      October 3 Southeast Asia launch will add distribution reaching approximately 68 million householdsNEW YORK CITY, NY / ACCESS Newswire / September 5, 2026 / , the 18-year media brand serving public companies and companies aspiring to enter the public markets, today announced its latest broadcast airing at 6:30 PM ET across Bloomberg Television in the United States, Latin America and the Middle East and North Africa (MENA).The program features executive interviews and corporate updates from Lanter

      Sep 5Yahoo FinanceLTRN
      Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Aug 21The Globe and MailLTRN

      This is the newest page. Registered accounts read further back.